Kyrgyzstan Essential Medical Devices List 2026-2028: Public Procurement Versus Market Access Registration

1. Key takeaways

In early October 2026, the Cabinet of Ministers of the Kyrgyz Republic approved the National List of Essential Medicines and Nationally Important Medical Devices for 2026–2028, signed by the Chairman of the Cabinet of Ministers, Adylbek Kasymaliev. This list governs what the public system buys and covers, which is a separate procedure from whether a product can be placed on the market. Inclusion in the list does not waive the state registration obligation; completing state registration does not automatically place a product on the list. Confusing the two is the most common misallocation of time and resources that companies make in the public procurement market.

2. Legal basis

1. Resolution of the Cabinet of Ministers of the Kyrgyz Republic on approving the National List of Essential Medicines and Nationally Important Medical Devices for 2026–2028 (early October 2026), signed by the Chairman of the Cabinet of Ministers, Adylbek Kasymaliev; the text of the resolution was published on the government portal.
2. Reports by the Kyrgyz official news agency and mainstream media (October 2026): the list was drawn up based on the World Health Organization Model List of Essential Medicines, the epidemiological situation in Kyrgyzstan, safety, clinical effectiveness and affordability, and for the first time provides separately for the approval of a national vaccines list covering the next three years.
3. Articles 14 and 15 of Law No. 216: state registration and the attributes of the registration certificate.
4. Cabinet Resolution No. 513, August 27, 2024: the state registration and appraisal procedure.
5. Article 29 of Law No. 216: import requires a national register record or an import permit conclusion.

Source note: the specific number and article-by-article content of the list resolution were not available this round in official wording suitable for verbatim citation. The statements above are based on reports by the Kyrgyz official news agency and mainstream media (grade B sources); specific application must follow the original text of the cabinet resolution.

3. Expert insights

Insight one: the dividing line between the two procedures is who is buying.

Market access registration answers whether a product may enter the market — it is required for sale through any channel. The list answers what the public system procures — it matters only in the contexts of government procurement, insurance reimbursement and public health programs. One is market access; the other is a procurement catalog. When planning public-market business, companies should advance both tracks in parallel rather than waiting for the list first.

Insight two: the criteria for drawing up the list differ from the technical criteria for registration.

The list was drawn up taking four factors into account: the World Health Organization Model List of Essential Medicines, the national epidemiological situation, safety, clinical effectiveness and affordability. Note the last factor — affordability. It is a dimension unique to the procurement perspective and does not arise at the registration stage. This means that a technically fully compliant product may be left off the list on price grounds, and the reverse is equally true.

Insight three: the update cycle of the list sets the rhythm for public-market business.

The list covers the three years 2026–2028. This gives companies a predictable reference rhythm: if a product is to enter the next round of the list, it is necessary to learn in advance how the list is adjusted and when the application window opens. We recommend having the authorized representative track the related publications of the Ministry of Health.

Insight four: the public procurement market is sizable, but the entry point is tendering, not the list.

Country-level research reports by multilateral institutions identify government procurement and international assistance programs (the Ministry of Health, state hospitals, and projects of the World Bank and the Global Fund) as one of the drivers of the Kyrgyz market. The list determines which categories will be procured, but the actual procurement takes place through tenders. The public-market pathway for a company is therefore: complete registration → monitor list coverage → track tender announcements → bid with local distributors.

Insight five: international assistance programs have dedicated registration arrangements, which deserve separate attention.

Country-level research reports by multilateral institutions expressly record that equipment registration fees under grant projects follow a dedicated rate (1,422 soms per model), and that the Kyrgyz side agreed in meeting minutes to take dedicated measures for projects, including possible exemptions or simplified registration, as well as extending the validity of the relevant legislation. For companies participating in international assistance programs, this is a channel worth exploring.

4. Practical recommendations

First, advance the two tracks in parallel. We recommend treating completion of state registration and tracking of the list and tenders as two independent but parallel lines in the project plan, each with its own objectives and timetable.

Second, have the authorized representative track the list and tender information. We recommend specifying in the representative’s duties the tracking of list adjustments and tender announcements on the Ministry of Health and government procurement platforms, with periodic reports to the manufacturer.

Third, assess affordability for public-market business. We recommend evaluating the price competitiveness of the product locally before bidding — affordability is a stated factor in drawing up the list, and this dimension carries through into procurement.

Fourth, participants in international assistance programs should proactively inquire about dedicated arrangements. We recommend communicating with the implementing agencies and the Ministry of Health to confirm whether dedicated registration facilitation measures exist, and retaining written replies.

Fifth, track the device list and the vaccines list separately. For the first time, this round of list preparation provides separately for approving a national vaccines list for the next three years. If your products involve vaccine-related devices (such as inoculation equipment or cold chain equipment), we recommend tracking the two lists separately.

5. Verification checklist

• □ The two procedures are clearly distinguished: market access registration (whether the product can be marketed) versus the list (what the public system procures);
• □ The project plan advances both tracks in parallel: completing state registration plus tracking the list and tenders;
• □ The authorized representative’s duties expressly include tracking list adjustments and tender announcements with periodic reports;
• □ Public-market business has assessed the affordability of the product (one of the factors for drawing up the list);
• □ Participants in international assistance programs have proactively asked whether dedicated registration facilitation measures exist;
• □ The original text of the cabinet resolution on the 2026–2028 list has been obtained to verify the specific items.

Regulatory information verified as of October 29, 2026.

Our services cover pre-market pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, manufacturing site inspection coordination, quality management system conformity support, post-market surveillance and vigilance system setup, import and distribution compliance, and fee calculation and project budget management.

The GRZAN regulatory team consists of professionals with many years of hands-on experience in Eurasian Economic Union registrations and has built stable local cooperation networks in Bishkek, Almaty, Tashkent and Moscow. Working in Chinese, Russian and English, we deliver actionable solutions for foreign manufacturers on the key issues commonly encountered in CIS markets, including authorized representative arrangements, notarization and legalization chains for powers of attorney, localization of technical documentation, and inspection readiness.

We hold to one principle: every regulatory conclusion we publish must be traceable to verifiable official sources; figures and timelines that cannot be verified are always marked as practical estimates and are never presented as legal requirements drawn from experience.

GRZAN provides registration and compliance support in this country for manufacturers, importers and authorized representatives. For project inquiries on market access in Kyrgyzstan or the Eurasian Economic Union, please contact us at info@grzanglobal.com.

GRZAN | Global Regulatory Registration and Compliance Services for Medical Devices